IDNA vs SPY
iShares Genomics Immunology and Healthcare ETF vs State Street SPDR S&P 500 ETF Trust
Which is better, IDNA or SPY?
Mid Cap Growth against Large Cap Blend.
SPY has a lower expense ratio. IDNA led over 1Y and 3Y, SPY over 5Y and the full window. SPY is less concentrated, with 38.0% of the fund in its ten largest positions against 43.5%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | IDNA | SPY |
|---|---|---|
| Expense Ratio | 0.47% | 0.09%Best |
| AUM | $257M | $814.4B |
| Dividend Yield | 0.86% | 1.01% |
| Holdings | 62 | 505 |
| YTD Return | +52.32%Best | +13.34% |
| 1Y Return | +78.00%Best | +19.97% |
| 3Y Return (annualized) | +22.29%Best | +21.20% |
| 5Y Return (annualized) | -5.36% | +12.81%Best |
| Volatility (annualized) | 26.0% | 16.4%Best |
| Max Drawdown | -68.3% | -34.1%Best |
| $10,000 over 5 years | $7,592 | $18,270Best |
| Top 10 Weight | 43.5% | 38.0%Best |
| Fund Family | iShares by BlackRock (US) | State Street Investment Management |
| Category | Equity | Equity |
| Style | Mid Cap Growth | Large Cap Blend |
| Inception | Jun 11, 2019 | Jan 22, 1993 |
Volatility and max drawdown are measured over the window both funds cover: Jun 13, 2019 to Sep 4, 2026 (7.2 years).
IDNA vs SPY growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 7.2 years both funds cover.
IDNA vs SPY Performance
iShares Genomics Immunology and Healthcare ETF (IDNA) is an ETF from iShares by BlackRock (US) and State Street SPDR S&P 500 ETF Trust (SPY) is an ETF from State Street Investment Management. Over the past year IDNA returned +78.00% while SPY returned +19.97%. Year to date, IDNA is up 52.32% versus a gain of 13.34% for SPY.
Over three years, IDNA compounded at +22.29% per year against +21.20% for SPY; over five years the annualized figures are -5.36% and +12.81% respectively. Across the full 7-year window we track, SPY has the edge at +15.67% annualized vs +7.40%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
IDNA has been the more volatile fund, with annualized monthly volatility of 26.0% compared with 16.4% for SPY. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -68.3% for IDNA and -34.1% for SPY. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.57. They move together some of the time, and apart the rest.
Fees and Cost Over Time
IDNA charges 0.47% per year while SPY charges 0.09%. On a $10,000 position that is $47 vs $9 annually, a gap of $38 per year that compounds over a long holding period. On income, IDNA currently yields 0.86% against 1.01% for SPY.
Holdings Overlap
24.0% of IDNA's money is in holdings SPY also owns. 1.1% of SPY's money is in holdings IDNA also owns.
IDNA and SPY share little of their money.
7 positions in common, counted across the 50 positions we hold weights for in IDNA and 504 in SPY, against full books of 62 and 505.
What only one of them owns
Our book lists 489 positions for SPY that do not appear in our book for IDNA (98.3% of the fund), and 26 for IDNA that do not appear in SPY (40.6%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in IDNA | Weight in SPY | Difference |
|---|---|---|---|
| REGNRegeneron Pharmaceuticals, Inc. | 4.26% | 0.11% | 4.15% |
| MRNAModerna therapeutics | 4.18% | 0.03% | 4.15% |
| MRKMerck & Company Inc | 3.74% | 0.47% | 3.27% |
| INCYIncyte Corp. | 4.12% | 0.03% | 4.09% |
| VRTXNvaesrtex Pharmaceuticals Inc | 3.82% | 0.18% | 3.64% |
| ROPRoper Technologies Inc. | 3.86% | 0.06% | 3.80% |
| GILDGilead Sciences Inc | 0.00% | 0.25% | 0.25% |
24.0% of IDNA is already inside SPY.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, IDNA or SPY?
IDNA has an expense ratio of 0.47% while SPY charges 0.09%. SPY is the cheaper option, by $38 a year on a $10,000 investment.
Which performed better, IDNA or SPY?
Over the past year IDNA returned +78.00% vs +19.97% for SPY, so IDNA leads on 1-year performance. Over the longest common window we track (7 years), IDNA annualized +7.40% vs +15.67% for SPY. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, IDNA or SPY?
IDNA has been the more volatile fund at 26.0% annualized versus 16.4% for SPY. Worst drawdown: IDNA -68.3% vs SPY -34.1%.
Should I hold both IDNA and SPY?
IDNA and SPY have a monthly-return correlation of 0.57, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between IDNA and SPY?
24.0% of IDNA's money is in holdings SPY also owns. 1.1% of SPY's is in holdings IDNA also owns. They hold 7 positions in common, counted across the 50 positions we hold weights for in IDNA and 504 in SPY.
Which pays a higher dividend, IDNA or SPY?
IDNA yields 0.86% while SPY yields 1.01%, so SPY currently pays the higher dividend yield.
Is SPY better than IDNA?
SPY has a lower expense ratio. IDNA led over 1Y and 3Y, SPY over 5Y and the full window. SPY is less concentrated, with 38.0% of the fund in its ten largest positions against 43.5%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.